Vancouver-based ID Biomedical gets NIH grant to develop plague vaccine

BOTHELL, Wash. (AP) - Vaccine developer ID Biomedical Corp. said Tuesday that it received a U.S. National Institutes of Health grant worth up to $8 million US to develop a nasally delivered vaccine against the plague, using the company's Proteosome technology. ...More